Evidence map›Paper›PMID 30446655›Full record

SynthesisNPJ primary care respiratory medicine2018

Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD.

Janwillem W H Kocks, Henry Chrystyn, Job van der Palen, Mike Thomas, Louisa Yates, Sarah H Landis, Maurice T Driessen, Mugdha Gokhale, Raj Sharma, Mathieu Molimard

Registry-linked trialOpen access · goldAbstract readSystematic Review
In one paragraph

Synthesis in NPJ primary care respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02813200 (Description of the Ability to Learn How to Handle Inhaler Devices in COPD), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02813200 phase4completednot on this map

Description of the Ability to Learn How to Handle Inhaler Devices in COPD

TypeinterventionalSponsorUniversity Hospital, BordeauxRan2017 to 2019Enrolled24ConditionsChronic Obstructive Pulmonary Disease (COPD)ArmsSeretide® Diskus® 500/550 μg, Ultibro® Breezhaler® 110/50 μg, Spiriva® Respimat® 2,5 μg
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Observational
  7. Article
  8. The value of treatable traits across the spectrum of adult asthma severity.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Validation of an AI-Powered Smart Dry Powder Inhaler (RS01X) for Asthma and COPD in a Clinical Setting.International journal of chronic obstructive pulmonary disease · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024
    Article
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Janwillem W H KocksGeneral Practitioners Research Institute, Groningen, The Netherlands. j.w.h.kocks@umcg.nl.ORCID http://orcid.org/0000-0002-2760-0693
Henry ChrystynInhalation Consultancy Ltd, Yeadon, UK.
Job van der PalenDepartment of Research Methodology, Measurement, and Data Analysis, Faculty of Behavioural, Management and Social Sciences, and Department of Epidemiology, Medisch Spectrum Twente, University of Twente, Enschede, The Netherlands.
Mike ThomasPrimary Care and Population Sciences, University of Southampton, Southampton, UK.
Louisa YatesGSK, Value Evidence & Outcomes, Brentford, UK.
Sarah H LandisGSK, Real World Evidence & Epidemiology, Uxbridge, UK.
Maurice T DriessenGSK, Value Evidence & Outcomes, Brentford, UK.
Mugdha GokhaleGSK, Real World Evidence & Epidemiology, Collegeville, PA, USA.
Raj SharmaGSK, Value Evidence & Outcomes, Brentford, UK.
Mathieu MolimardDepartment of Pharmacology, University of Bordeaux, Bordeaux, France.
Health Economics and Outcomes Research (United Kingdom) · GB21c Consultancy (United Kingdom) · GBGeneral Practitioners Research Institute · NLGlaxoSmithKline (United States) · USMedisch Spectrum Twente · NLNIHR Southampton Biomedical Research Centre · GBUniversité de Bordeaux · FR

Funding

GlaxoSmithKline (GlaxoSmithKline Plc.) NA
6 · The paper itself

Abstract

Inhaled medications are the cornerstone of treatment and management of asthma and COPD. However, inhaler device errors are common among patients and have been linked with reduced symptom control, an increased risk of exacerbations, and increased healthcare utilisation. These observations have prompted GINA (Global INitiative for Asthma) and GOLD (Global initiative for chronic Obstructive Lung Disease) to recommend regular assessment of inhaler technique in a bid to improve therapeutic outcomes. To better define the relationship between device errors and health outcomes (clinical outcomes, quality of life, and healthcare utilisation) in asthma and COPD, we conducted a systematic review of the literature, with a particular focus on the methods used to assess the relationship between device errors and outcomes. Sixteen studies were identified (12 in patients with asthma, one in patients with COPD, and three in both asthma and COPD) with varying study designs, endpoints, and patient populations. Most of the studies reported that inhalation errors were associated with worse disease outcomes in patients with asthma or COPD. Patients who had a reduction in errors over time had improved outcomes. These findings suggest that time invested by healthcare professionals is vital to improving inhalation technique in asthma and COPD patients to improve health outcomes.

Indexed as

Medication ErrorsAdministration, InhalationAsthmaHumansPulmonary Disease, Chronic ObstructiveTreatment Outcome

Identifiers

PMID30446655
PMCPMC6240098
OpenAlexW2901932540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.